Structural insights into endoplasmic reticulum stored calcium regulation by inositol 1,4,5-trisphosphate and ryanodine receptors

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 9, 2014, Pages 1980-1991

  Seo, Min Duk ^a   Enomoto, Masahiro ^b   Ishiyama, Noboru ^b   Stathopulos, Peter B ^c   Ikura, Mitsuhiko ^b  

^a Ajou University   (South Korea)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

Calcium release channel; Calcium signaling; Electron microscopy (EM); Inositol 1,4,5 trisphosphate receptor (IP3R); Nuclear magnetic resonance (NMR); Protein structure; Ryanodine receptor (RyR); X ray crystallography

Indexed keywords

INOSITOL 1,4,5 TRISPHOSPHATE; RYANODINE RECEPTOR;

ATAXIA; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL FUNCTION; CRYOELECTRON MICROSCOPY; CRYSTAL STRUCTURE; ENDOPLASMIC RETICULUM; EXOCRINE SECRETION DEFICIT; GENE MUTATION; HEART DISEASE; HUMAN; HUNTINGTON CHOREA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; REVIEW; TASTE PERCEPTION DEFICIT; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ENDOPLASMIC RETICULUM; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; PROTEIN STRUCTURE, TERTIARY; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84952628203     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.11.023     Document Type: Review

References (147)

1. Berridge M.J. Inositol trisphosphate and calcium signalling. Nature 1993, 361:315-325.
2. Clapham D.E. Calcium signaling. Cell 1995, 80:259-268.
3. Clapham D.E. Calcium signaling. Cell 2007, 131:1047-1058.
4. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 2003, 4:517-529.
5. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000, 1:11-21.
6. 2+ release channels. Physiol. Rev. 2007, 87:593-658.
7. Lanner J.T., Georgiou D.K., Joshi A.D., Hamilton S.L. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb. Perspect. Biol. 2010, 2:a003996.
8. 2+ release channel of sarcoplasmic reticulum. J. Biol. Chem. 1986, 261:6300-6306.
9. Bezprozvanny I., Watras J., Ehrlich B.E. Bell-shaped calcium-response curves of Ins (1,4,5) P3- and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature 1991, 351:751-754.
10. Roderick H.L., Bootman M.D. Calcium influx: is Homer the missing link?. Curr. Biol. 2003, 13:R976-R978.
11. Bezprozvanny I. The inositol 1,4,5-trisphosphate receptors. Cell Calcium 2005, 38:261-272.
12. Ottini L., Marziali G., Conti A., Charlesworth A., Sorrentino V. Alpha and beta isoforms of ryanodine receptor from chicken skeletal muscle are the homologues of mammalian RyR1 and RyR3. Biochem. J. 1996, 315(Pt 1):207-216.
13. Sugawara H., Kurosaki M., Takata M., Kurosaki T. Genetic evidence for involvement of type 1, type 2 and type 3 inositol 1,4,5-trisphosphate receptors in signal transduction through the B-cell antigen receptor. EMBO J. 1997, 16:3078-3088.
14. Berridge M.J. Calcium hypothesis of Alzheimer's disease. Pflugers Arch. 2010, 459:441-449.
15. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 2009, 15:89-100.
16. Bezprozvanny I. Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias. Neurochem. Res. 2011, 36:1186-1197.
17. Bezprozvanny I., Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008, 31:454-463.
18. Fiorio Pla A., Avanzato D., Munaron L., Ambudkar I.S. Ion channels and transporters in cancer. 6. Vascularizing the tumor: TRP channels as molecular targets. Am. J. Physiol. Cell Physiol. 2012, 302:C9-C15.
19. 2+ release channels in neurological diseases. Pflugers Arch. 2010, 460:481-494.
20. Lehen'kyi V., Shapovalov G., Skryma R., Prevarskaya N. Ion channnels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. Am. J. Physiol. Cell Physiol. 2011, 301:C1281-C1289.
21. Prevarskaya N., Skryma R., Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat. Rev. Cancer 2011, 11:609-618.
22. Rizzuto R., Pinton P., Ferrari D., Chami M., Szabadkai G., Magalhaes P.J., Di Virgilio F., Pozzan T. Calcium and apoptosis: facts and hypotheses. Oncogene 2003, 22:8619-8627.
23. 2+ for cancer cell proliferation and survival. Nat. Rev. Cancer 2008, 8:361-375.
24. Whitfield J.F. Calcium signals and cancer. Crit. Rev. Oncog. 1992, 3:55-90.
25. Lee J.M., Davis F.M., Roberts-Thomson S.J., Monteith G.R. Ion channels and transporters in cancer. 4. Remodeling of Ca(2+) signaling in tumorigenesis: role of Ca(2+) transport. Am. J. Physiol. Cell Physiol. 2011, 301:C969-C976.
26. Monteith G.R., Davis F.M., Roberts-Thomson S.J. Calcium channels and pumps in cancer: changes and consequences. J. Biol. Chem. 2012, 287:31666-31673.
27. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
28. Kang S.S., Han K.S., Ku B.M., Lee Y.K., Hong J., Shin H.Y., Almonte A.G., Woo D.H., Brat D.J., Hwang E.M., Yoo S.H., Chung C.K., Park S.H., Paek S.H., Roh E.J., Lee S.J., Park J.Y., Traynelis S.F., Lee C.J. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res. 2010, 70:1173-1183.
29. Shibao K., Fiedler M.J., Nagata J., Minagawa N., Hirata K., Nakayama Y., Iwakiri Y., Nathanson M.H., Yamaguchi K. The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma. Cell Calcium 2010, 48:315-323.
30. Li C., Wang X., Vais H., Thompson C.B., Foskett J.K., White C. Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12565-12570.
31. Rong Y.P., Aromolaran A.S., Bultynck G., Zhong F., Li X., McColl K., Matsuyama S., Herlitze S., Roderick H.L., Bootman M.D., Mignery G.A., Parys J.B., De Smedt H., Distelhorst C.W. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol. Cell 2008, 31:255-265.
32. Rong Y.P., Bultynck G., Aromolaran A.S., Zhong F., Parys J.B., De Smedt H., Mignery G.A., Roderick H.L., Bootman M.D., Distelhorst C.W. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14397-14402.
33. White C., Li C., Yang J., Petrenko N.B., Madesh M., Thompson C.B., Foskett J.K. The endoplasmic reticulum gateway to apoptosis by Bcl-x(L) modulation of the InsP3R. Nat. Cell Biol. 2005, 7:1021-1028.
34. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
35. 2+ levels in colorectal cancer cell lines. J. Cell Sci. 2014.
36. Sung P.J., Tsai F.D., Vais H., Court H., Yang J., Fehrenbacher N., Foskett J.K., Philips M.R. Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20593-20598.
37. Etcheberrigaray R., Hirashima N., Nee L., Prince J., Govoni S., Racchi M., Tanzi R.E., Alkon D.L. Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol. Dis. 1998, 5:37-45.
38. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:534-538.
39. Stutzmann G.E. The pathogenesis of Alzheimers disease is it a lifelong "calciumopathy"?. Neuroscientist 2007, 13:546-559.
40. 2+ signals and altered membrane excitability. J. Neurosci.: Off. J. Soc. Neurosci. 2004, 24:508-513.
41. 2+ leak function of presenilin 1. J. Clin. Invest. 2007, 117:1230-1239.
42. 2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 2006, 126:981-993.
43. Zhang H., Sun S., Herreman A., De Strooper B., Bezprozvanny I. Role of presenilins in neuronal calcium homeostasis. J. Neurosci.: Off. J. Soc. Neurosci. 2010, 30:8566-8580.
44. Cheung K.H., Mei L., Mak D.O., Hayashi I., Iwatsubo T., Kang D.E., Foskett J.K. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. Sci. Signal. 2010, 3:ra22.
45. 2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 2008, 58:871-883.
46. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
47. Tobin A.J., Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 2000, 10:531-536.
48. Tang T.S., Tu H., Chan E.Y., Maximov A., Wang Z., Wellington C.L., Hayden M.R., Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
49. Kaltenbach L.S., Romero E., Becklin R.R., Chettier R., Bell R., Phansalkar A., Strand A., Torcassi C., Savage J., Hurlburt A., Cha G.H., Ukani L., Chepanoske C.L., Zhen Y., Sahasrabudhe S., Olson J., Kurschner C., Ellerby L.M., Peltier J.M., Botas J., Hughes R.E. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007, 3:e82.
50. Higo T., Hamada K., Hisatsune C., Nukina N., Hashikawa T., Hattori M., Nakamura T., Mikoshiba K. Mechanism of ER stress-induced brain damage by IP(3) receptor. Neuron 2010, 68:865-878.
51. Takeshima H., Nishimura S., Matsumoto T., Ishida H., Kangawa K., Minamino N., Matsuo H., Ueda M., Hanaoka M., Hirose T., et al. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature 1989, 339:439-445.
52. Brandom B.W., Larach M.G., Chen M.S., Young M.C. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth. Analg. 2011, 112:1115-1123.
53. Durham W.J., Aracena-Parks P., Long C., Rossi A.E., Goonasekera S.A., Boncompagni S., Galvan D.L., Gilman C.P., Baker M.R., Shirokova N., Protasi F., Dirksen R., Hamilton S.L. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 2008, 133:53-65.
54. Hwang J.H., Zorzato F., Clarke N.F., Treves S. Mapping domains and mutations on the skeletal muscle ryanodine receptor channel. Trends Mol. Med. 2012, 18:644-657.
55. Jurkat-Rott K., McCarthy T., Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000, 23:4-17.
56. Avila G., Dirksen R.T. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J. Gen. Physiol. 2001, 118:277-290.
57. Jungbluth H. Central core disease. Orphanet J Rare Dis. 2007, 2:25.
58. Robinson R.L., Brooks C., Brown S.L., Ellis F.R., Halsall P.J., Quinnell R.J., Shaw M.A., Hopkins P.M. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum. Mutat. 2002, 20:88-97.
59. Jungbluth H. Multi-minicore disease. Orphanet J Rare Dis. 2007, 2:31.
60. Van Petegem F. Ryanodine receptors: structure and function. J. Biol. Chem. 2012, 287:31624-31632.
61. Capacchione J.F., Muldoon S.M. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth. Analg. 2009, 109:1065-1069.
62. Paul-Pletzer K., Yamamoto T., Bhat M.B., Ma J., Ikemoto N., Jimenez L.S., Morimoto H., Williams P.G., Parness J. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J. Biol. Chem. 2002, 277:34918-34923.
63. 2+ release channels. Molecular mechanism and isoform selectivity. J. Biol. Chem. 2001, 276:13810-13816.
64. Szentesi P., Collet C., Sarkozi S., Szegedi C., Jona I., Jacquemond V., Kovacs L., Csernoch L. Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. J. Gen. Physiol. 2001, 118:355-375.
65. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J. Biol. Chem. 1990, 265:13472-13483.
66. Nakai J., Imagawa T., Hakamat Y., Shigekawa M., Takeshima H., Numa S. Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel. FEBS Lett. 1990, 271:169-177.
67. Laitinen P.J., Brown K.M., Piippo K., Swan H., Devaney J.M., Brahmbhatt B., Donarum E.A., Marino M., Tiso N., Viitasalo M., Toivonen L., Stephan D.A., Kontula K. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001, 103:485-490.
68. 2+ handling and arrhythmogenesis. Circ. Res. 2011, 108:871-883.
69. 2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J. Physiol. 2009, 587:3113-3115.
70. 2+-triggered arrhythmias. Nat. Med. 2014, 20:184-192.
71. Liu N., Colombi B., Memmi M., Zissimopoulos S., Rizzi N., Negri S., Imbriani M., Napolitano C., Lai F.A., Priori S.G. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ. Res. 2006, 99:292-298.
72. Watanabe H., Chopra N., Laver D., Hwang H.S., Davies S.S., Roach D.E., Duff H.J., Roden D.M., Wilde A.A., Knollmann B.C. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat. Med. 2009, 15:380-383.
73. 2+ spark mass. J Mol. Cell Cardiol. 2010, 48:293-301.
74. Liu J., Supnet C., Sun S., Zhang H., Good L., Popugaeva E., Bezprozvanny I. The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Channels 2014, 8.
75. Bruno A.M., Huang J.Y., Bennett D.A., Marr R.A., Hastings M.L., Stutzmann G.E. Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2012, 33(1001):e1001-e1006.
76. Bosanac I., Alattia J.R., Mal T.K., Chan J., Talarico S., Tong F.K., Tong K.I., Yoshikawa F., Furuichi T., Iwai M., Michikawa T., Mikoshiba K., Ikura M. Structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with its ligand. Nature 2002, 420:696-700.
77. Bosanac I., Yamazaki H., Matsu-Ura T., Michikawa T., Mikoshiba K., Ikura M. Crystal structure of the ligand binding suppressor domain of type 1 inositol 1,4,5-trisphosphate receptor. Mol. Cell 2005, 17:193-203.
78. Seo M.D., Velamakanni S., Ishiyama N., Stathopulos P.B., Rossi A.M., Khan S.A., Dale P., Li C., Ames J.B., Ikura M., Taylor C.W. Structural and functional conservation of key domains in InsP3 and ryanodine receptors. Nature 2012, 483:108-112.
79. Lin C.C., Baek K., Lu Z. Apo and InsP-bound crystal structures of the ligand-binding domain of an InsP receptor. Nat. Struct. Mol. Biol. 2011, 18:1172-1174.
80. Yoshikawa F., Morita M., Monkawa T., Michikawa T., Furuichi T., Mikoshiba K. Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor. J. Biol. Chem. 1996, 271:18277-18284.
81. Chan J., Yamazaki H., Ishiyama N., Seo M.-D., Mal T.K., Michikawa T., Mikoshiba K., Ikura M. Structural studies of inositol 1,4,5-trisphosphate receptor: coupling ligand binding to channel gating. J. Biol. Chem. 2010, 285:36092-36099.
82. Iwai M., Michikawa T., Bosanac I., Ikura M., Mikoshiba K. Molecular basis of the isoform-specific ligand-binding affinity of inositol 1,4,5-trisphosphate receptors. J. Biol. Chem. 2007, 282:12755-12764.
83. Amador F.J., Liu S., Ishiyama N., Plevin M.J., Wilson A., MacLennan D.H., Ikura M. Crystal structure of type I ryanodine receptor amino-terminal beta-trefoil domain reveals a disease-associated mutation "hot spot" loop. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11040-11044.
84. Lobo P.A., Van Petegem F. Crystal structures of the N-terminal domains of cardiac and skeletal muscle ryanodine receptors: insights into disease mutations. Structure 2009, 17:1505-1514.
85. Lobo P.A., Kimlicka L., Tung C.C., Van Petegem F. The deletion of exon 3 in the cardiac ryanodine receptor is rescued by beta strand switching. Structure 2011, 19:790-798.
86. Tung C.C., Lobo P.A., Kimlicka L., Van Petegem F. The amino-terminal disease hotspot of ryanodine receptors forms a cytoplasmic vestibule. Nature 2010, 468:585-588.
87. Kimlicka L., Lau K., Tung C.C., Van Petegem F. Disease mutations in the ryanodine receptor N-terminal region couple to a mobile intersubunit interface. Nat. Commun. 2013, 4:1506.
88. Sharma P., Ishiyama N., Nair U., Li W., Dong A., Miyake T., Wilson A., Ryan T., MacLennan D.H., Kislinger T., Ikura M., Dhe-Paganon S., Gramolini A.O. Structural determination of the phosphorylation domain of the ryanodine receptor. FEBS J. 2012, 279:3952-3964.
89. Yuchi Z., Lau K., Van Petegem F. Disease mutations in the ryanodine receptor central region: crystal structures of a phosphorylation hot spot domain. Structure 2012, 20:1201-1211.
90. Mignery G.A., Newton C.L., Archer B.T., Südhof T.C. Structure and expression of the rat inositol 1,4,5-trisphosphate receptor. J. Biol. Chem. 1990, 265:12679-12685.
91. Smith J.S., Imagawa T., Ma J., Fill M., Campbell K.P., Coronado R. Purified ryanodine receptor from rabbit skeletal muscle is the calcium-release channel of sarcoplasmic reticulum. J. Gen. Physiol. 1988, 92:1-26.
92. Ludtke S.J., Serysheva I.I., Hamilton S.L., Chiu W. The pore structure of the closed RyR1 channel. Structure 2005, 13:1203-1211.
93. Samsó M., Wagenknecht T., Allen P.D. Internal structure and visualization of transmembrane domains of the RyR1 calcium release channel by cryo-EM. Nat. Struct. Mol. Biol. 2005, 12:539-544.
94. Ludtke S.J., Serysheva I.I. Single-particle Cryo-EM of calcium release channels: structural validation. Curr. Opin. Struct. Biol. 2013, 23:755-762.
95. Ludtke S.J., Tran T.P., Ngo Q.T., Moiseenkova-Bell V.Y., Chiu W., Serysheva I.I. Flexible architecture of IP(3)R1 by Cryo-EM. Structure 2011, 19:1192-1199.
96. Murray S.C., Flanagan J., Popova O.B., Chiu W., Ludtke S.J., Serysheva I.I. Validation of cryo-EM structure of IP[U+2083]R1 channel. Structure 2013, 21:900-909.
97. Wriggers W., Birmanns S. Using situs for flexible and rigid-body fitting of multiresolution single-molecule data. J. Struct. Biol. 2001, 133:193-202.
98. Zissimopoulos S., Viero C., Seidel M., Cumbes B., White J., Cheung I., Stewart R., Jeyakumar L.H., Fleischer S., Mukherjee S., Thomas N.L., Williams A.J., Lai F.A. N-terminus oligomerization regulates the function of cardiac ryanodine receptors. J. Cell Sci. 2013, 126:5042-5051.
99. Zissimopoulos S., Marsh J., Stannard L., Seidel M., Lai F.A. N-terminus oligomerization is conserved in intracellular calcium release channels. Biochem. J. 2014, 459:265-273.
100. 2+ sensor protein, inhibits inositol trisphosphate receptors by clamping intersubunit interactions. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8507-8512.
101. Samso M., Feng W., Pessah I.N., Allen P.D. Coordinated movement of cytoplasmic and transmembrane domains of RyR1 upon gating. PLoS Biol. 2009, 7:e85.
102. Zhong X., Liu Y., Zhu L., Meng X., Wang R., Van Petegem F., Wagenknecht T., Chen S.R., Liu Z. Conformational dynamics inside amino-terminal disease hotspot of ryanodine receptor. Structure 2013, 21:2051-2060.
103. Kimlicka L., Tung C.C., Carlsson A.C., Lobo P.A., Yuchi Z., Van Petegem F. The cardiac ryanodine receptor N-terminal region contains an anion binding site that is targeted by disease mutations. Structure 2013, 21:1440-1449.
104. Medeiros-Domingo A., Bhuiyan Z.A., Tester D.J., Hofman N., Bikker H., van Tintelen J.P., Mannens M.M., Wilde A.A., Ackerman M.J. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J. Am. Coll. Cardiol. 2009, 54:2065-2074.
105. Lau K., Chan M.M., Van Petegem F. Lobe-specific calmodulin binding to different ryanodine receptor isoforms. Biochemistry 2014, 53:932-946.
106. Nyegaard M., Overgaard M.T., Sondergaard M.T., Vranas M., Behr E.R., Hildebrandt L.L., Lund J., Hedley P.L., Camm A.J., Wettrell G., Fosdal I., Christiansen M., Borglum A.D. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am. J. Hum. Genet. 2012, 91:703-712.
107. Ibarra M.C., Wu S., Murayama K., Minami N., Ichihara Y., Kikuchi H., Noguchi S., Hayashi Y.K., Ochiai R., Nishino I. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006, 104:1146-1154.
108. Chan J., Whitten A.E., Jeffries C.M., Bosanac I., Mal T.K., Ito J., Porumb H., Michikawa T., Mikoshiba K., Trewhella J., Ikura M. Ligand-induced conformational changes via flexible linkers in the amino-terminal region of the inositol 1,4,5-trisphosphate receptor. J. Mol. Biol. 2007, 373:1269-1280.
109. Yamazaki H., Chan J., Ikura M., Michikawa T., Mikoshiba K. Tyr-167/Trp-168 in type 1/3 inositol 1,4,5-trisphosphate receptor mediates functional coupling between ligand binding and channel opening. J. Biol. Chem. 2010, 285:36081-36091.
110. Boehning D., Joseph S.K. Direct association of ligand-binding and pore domains in homo- and heterotetrameric inositol 1,4,5-trisphosphate receptors. EMBO J. 2000, 19:5450-5459.
111. Schug Z.T., Joseph S.K. The role of the S4-S5 linker and C-terminal tail in inositol 1,4,5-trisphosphate receptor function. J. Biol. Chem. 2006, 281:24431-24440.
112. Finch E.A., Turner T.J., Goldin S.M. Calcium as a coagonist of inositol 1,4,5-trisphosphate-induced calcium release. Science 1991, 252:443-446.
113. 2+ dependence of inositol 1,4,5-trisphosphate-induced Ca release in smooth muscle cells of the guinea pig taenia caeci. J. Gen. Physiol. 1990, 95:1103-1122.
114. 2+. Cell Calcium 2002, 32:321-334.
115. 2+ regulation of inositol trisphosphate receptors. Biochem. J. 2001, 360:395-400.
116. Yamada M., Miyawaki A., Saito K., Nakajima T., Yamamoto-Hino M., Ryo Y., Furuichi T., Mikoshiba K. The calmodulin-binding domain in the mouse type 1 inositol 1,4,5-trisphosphate receptor. Biochem. J. 1995, 308(Pt 1):83-88.
117. Sun Y., Taylor C.W. A calmodulin antagonist reveals a calmodulin-independent interdomain interaction essential for activation of inositol 1,4,5-trisphosphate receptors. Biochem. J. 2008, 416:243-253.
118. Sun Y., Rossi A.M., Rahman T., Taylor C.W. Activation of IP3 receptors requires an endogenous 1-8-14 calmodulin-binding motif. Biochem. J. 2013, 449:39-49.
119. 2+ and calmodulin. J. Biol. Chem. 1999, 274:12157-12162.
120. Sienaert I., Nadif Kasri N., Vanlingen S., Parys J.B., Callewaert G., Missiaen L., de Smedt H. Localization and function of a calmodulin-apocalmodulin-binding domain in the N-terminal part of the type 1 inositol 1,4,5-trisphosphate receptor. Biochem. J. 2002, 365:269-277.
121. Mak D.O., McBride S.M., Petrenko N.B., Foskett J.K. Novel regulation of calcium inhibition of the inositol 1,4,5-trisphosphate receptor calcium-release channel. J. Gen. Physiol. 2003, 122:569-581.
122. Maeda N., Kawasaki T., Nakade S., Yokota N., Taguchi T., Kasai M., Mikoshiba K. Structural and functional characterization of inositol 1,4,5-trisphosphate receptor channel from mouse cerebellum. J. Biol. Chem. 1991, 266:1109-1116.
123. Lin C., Widjaja J., Joseph S.K. The interaction of calmodulin with alternatively spliced isoforms of the type-I inositol trisphosphate receptor. J. Biol. Chem. 2000, 275:2305-2311.
124. Hirota J., Michikawa T., Natsume T., Furuichi T., Mikoshiba K. Calmodulin inhibits inositol 1,4,5-trisphosphate-induced calcium release through the purified and reconstituted inositol 1,4,5-trisphosphate receptor type 1. FEBS Lett. 1999, 456:322-326.
125. 2+-independent inhibition of type-1 inositol trisphosphate receptors. Biochem. J. 1998, 334(Pt 2):447-455.
126. 2+ release mediated by type-1, -2 and -3 inositol trisphosphate receptors. Biochem. J. 2000, 345(Pt 2):357-363.
127. 2+-binding proteins. EMBO J. 2004, 23:312-321.
128. Yang J., McBride S., Mak D.O., Vardi N., Palczewski K., Haeseleer F., Foskett J.K. Identification of a family of calcium sensors as protein ligands of inositol trisphosphate receptor Ca(2+) release channels. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7711-7716.
129. 2+-dependent regulation of inositol 1,4,5-trisphosphate receptors by CaBP1. J. Biol. Chem. 2009, 284:2472-2481.
130. Hsueh C.H., Weng Y.C., Chen C.Y., Lin T.K., Lin Y.H., Lai L.P., Lin J.L. A novel mutation (Arg169Gln) of the cardiac ryanodine receptor gene causing exercise-induced bidirectional ventricular tachycardia. Int. J. Cardiol. 2006, 108:276-278.
131. Kannankeril P.J., Mitchell B.M., Goonasekera S.A., Chelu M.G., Zhang W., Sood S., Kearney D.L., Danila C.I., De Biasi M., Wehrens X.H., Pautler R.G., Roden D.M., Taffet G.E., Dirksen R.T., Anderson M.E., Hamilton S.L. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12179-12184.
132. Amador F.J., Kimlicka L., Stathopulos P.B., Gasmi-Seabrook G.M., Maclennan D.H., Van Petegem F., Ikura M. Type 2 ryanodine receptor domain A contains a unique and dynamic alpha-helix that transitions to a beta-strand in a mutant linked with a heritable cardiomyopathy. J. Mol. Biol. 2013, 425:4034-4046.
133. Bhuiyan Z.A., van den Berg M.P., van Tintelen J.P., Bink-Boelkens M.T., Wiesfeld A.C., Alders M., Postma A.V., van Langen I., Mannens M.M., Wilde A.A. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation 2007, 116:1569-1576.
134. 2+ binding site in the type I inositol 1,4,5-trisphosphate receptor. J. Biol. Chem. 1996, 271:27005-27012.
135. 2+-binding domains in the type 1 inositol 1,4,5-trisphosphate receptor. J. Biol. Chem. 1997, 272:25899-25906.
136. Miyakawa T., Mizushima A., Hirose K., Yamazawa T., Bezprozvanny I., Kurosaki T., Iino M. Ca(2+)-sensor region of IP(3) receptor controls intracellular Ca(2+) signaling. EMBO J. 2001, 20:1674-1680.
137. Tu H., Nosyreva E., Miyakawa T., Wang Z., Mizushima A., Iino M., Bezprozvanny I. Functional and biochemical analysis of the type 1 inositol (1,4,5)-trisphosphate receptor calcium sensor. Biophys. J. 2003, 85:290-299.
138. 2+ signaling 'toolkit' at the origin of metazoa. Mol. Biol. Evol. 2008, 25:1357-1361.
139. 2+ signaling machinery in early animal and fungal evolution. Mol. Biol. Evol. 2011, 29:91-100.
140. Prole D.L., Taylor C.W. Identification of intracellular and plasma membrane calcium channel homologues in pathogenic parasites. PLoS ONE 2011, 6:e26218.
141. Docampo R., Moreno S.N., Plattner H. Intracellular calcium channels in protozoa. Eur. J. Pharmacol. 2014, 739C:4-18.
142. Ladenburger E.M., Korn I., Kasielke N., Wassmer T., Plattner H. An Ins(1,4,5)P3 receptor in Paramecium is associated with the osmoregulatory system. J. Cell Sci. 2006, 119:3705-3717.
143. Ladenburger E.M., Plattner H. Calcium-release channels in Paramecium. Genomic expansion, differential positioning and partial transcriptional elimination. PLoS ONE 2011, 6:e27111.
144. Hashimoto M., Enomoto M., Morales J., Kurebayashi N., Sakurai T., Hashimoto T., Nara T., Mikoshiba K. Inositol 1,4,5-trisphosphate receptor regulates replication, differentiation, infectivity and virulence of the parasitic protist Trypanosoma cruzi. Mol. Microbiol. 2013, 87:1133-1150.
145. Huang G., Bartlett P.J., Thomas A.P., Moreno S.N., Docampo R. Acidocalcisomes of Trypanosoma brucei have an inositol 1,4,5-trisphosphate receptor that is required for growth and infectivity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:1887-1892.
146. Hashimoto M., Nara T., Hirawake H., Morales J., Enomoto M., Mikoshiba K. Antisense oligonucleotides targeting parasite inositol 1,4,5-trisphosphate receptor inhibits mammalian host cell invasion by Trypanosoma cruzi. Sci. Rep. 2014, 4:4231.
147. Stathopulos P.B., Seo M.D., Enomoto M., Amador F.J., Ishiyama N., Ikura M. Themes and variations in ER/SR calcium release channels: structure and function. Physiology (Bethesda) 2012, 27:331-342.